Table 2.

Rates and Relative Risks of Death before Assessment at 18 to 22 Months or Neurodevelopmental Impairment at 18 to 22 Months of Corrected Age in the CPAP and Surfactant Groups.^*

Variable	CPAP	Surfactant	Adjusted Relative Risk (95% CI)	P Value
number/total number (percent)
Primary outcome determined	621/663 (93.7)	613/653 (93.9)	1.00 (0.97–1.03)	0.83
Death or NDI	173/621 (27.9)	183/613 (29.9)	0.93 (0.78–1.10)	0.38
Death before assessment at 18–22 mo of corrected age	118/643 (18.4)	140/638 (21.9)	0.83 (0.67–1.04)	0.10
NDI	55/503 (10.9)	43/473 (9.1)	1.16 (0.79–1.71)	0.44
BSID-III cognitive score <70†	36/502 (7.2)	36/472 (7.6)	0.95 (0.61–1.50)	0.84
GMFCS score ≥2‡	26/511 (5.1)	23/479 (4.8)	0.98 (0.57–1.69)	0.95
Moderate or severe cerebral palsy	21/511 (4.1)	19/479 (4.0)	0.93 (0.51–1.72)	0.82
Bilateral blindness	4/511 (0.8)	7/479 (1.5)	0.53 (0.16–1.78)	0.31
Hearing impairment	17/511 (3.3)	7/479 (1.5)	2.27 (0.96–5.37)	0.06

^*Relative risks and P values were adjusted for stratification factors (study center and gestational-age group) and familial clustering; analyses of blindness were not adjusted for study center, owing to the small number of patients with this characteristic. NDI denotes neurodevelopmental impairment.

^†Scores on the Bayley Scales of Infant and Toddler Development, third edition (BSID-III), are assessed relative to a standardized mean (±SD) of 100±15, with higher scores indicating better performance.

^‡Gross-motor function was assessed by means of the modified Gross Motor Function Classification System (GMFCS), with scores ranging from 0 to 5 and higher scores indicating greater impairment.